Roche cobas® Strep A - CE Marked and FDA Cleared
The FDA has provided 510(k) clearance for the Roche cobas® Strep A test for the detection of group A streptococcus bacterial (Strep A) DNA in throat swab specimens. The cobas Strep A test runs on the cobas Liat System, a PCR based point of care diagnostic system, designed for on-demand testing in physician clinics, pharmacy, and hospital lab settings which will be launched later this year.
With a time to result of just 15 minutes, the cobas Strep A test achieves outstanding sensitivity aiding healthcare professionals to make immediate, informed treatment decisions in a variety of testing locations.
“The cobas Strep A test is easy to use and provides accurate results to support a treatment decision in just 15 minutes, much faster than current technologies,” said Roland Diggelmann, COO of Roche Diagnostics. “It also provides a significant improvement over conventional methods such as culture testing, where patients can wait up to 2 days to receive their result, or rapid antigen testing where confirmation with culture is needed due to significantly lower sensitivity.”
The new cobas Strep A test adds to the growing portfolio of assays designed for use with the cobas Liat System, enabling healthcare professionals to perform molecular PCR testing in a variety of settings with speed, accuracy, reliability and minimal training. The analyzer and two initial assays (cobas Influenza A/B and cobas Strep A) are both CE Marked and FDA cleared. Roche expects to begin sales of the system and assays later this year.
Tags: Group A Streptococcus
Date Published: December 8, 2014
Source article link: Roche Diagnostics » company contact details
FDA Clearance for Solana® Strep Complete Assay
New BD Veritor™ Plus System for Secure, Traceable POC
MASTASTREP™ Rapid Latex Test for Identification of Streptococci
First Applications for World's Smallest DNA-Testing Device
CLIA Waiver for Roche's cobas Liat PCR System and Strep A assay